NCT06142396 2026-03-12
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Augusta University
Phase EARLY_PHASE1 Recruiting
Clinical Trials
12 trialsNCT07458659 2026-03-09
CART-BCMA
Chulalongkorn University
Phase EARLY_PHASE1 Not yet recruiting
NCT07429721 2026-02-24
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Not yet recruiting
NCT07399444 2026-02-10
LB2505-0001
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT05093335 2026-02-05
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT06663046 2026-01-20
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma
Wondercel Biotech (ShenZhen)
Phase EARLY_PHASE1 Recruiting
NCT07185490 2026-01-20
IASO104
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT07336823 2026-01-13
JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma
Shenzhen Genocury Biotech Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT07322159 2026-01-07
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT06385652 2026-01-06
PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
Peking University First Hospital
Phase EARLY_PHASE1 Recruiting
NCT05560399 2026-01-02
CC-220
Icahn School of Medicine at Mount Sinai
Phase EARLY_PHASE1 Active not recruiting
NCT07294625 2025-12-19
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1 Recruiting